MAPT and Alzheimer disease: APOE-ε4 is associated with higher levels of Aβ42 and tau pathology, neurodegeneration, and with increased Ca2+ dysregulation, while APOE-ε2 offers protection against dementia and reduces AD risk (Morrison et al., 2024; Serrano-Pozo et al., 2015).